Literature DB >> 9008748

[Castleman's disease].

C Larroche1, P Cacoub, P Godeau.   

Abstract

Castleman's disease, also called angiofollicular lymph node hyperplasia was first described as a distinct entity by Castleman et al in 1956. Two forms are now described a localized and a multicentric. The clinical and biological signs are varied and heterogeneous, and the diagnostic is made on the histologic examination. This atypical lymphoproliferative disorder is of unknown origin, but interleukin 6 play a central part in this disease. Despite the benignity of this "prelymphoma state", an aggressive course with poor prognosis occur usually in the multicentric form. Malignant lymphomas and Kaposi's sarcoma have been associated with Castleman's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9008748     DOI: 10.1016/s0248-8663(97)80844-2

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  9 in total

1.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  [Retroperitoneal mass].

Authors:  P Käse; A Troja; H-R Raab
Journal:  Chirurg       Date:  2013-05       Impact factor: 0.955

Review 3.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

4.  Surgical management of abdominal and retroperitoneal Castleman's disease.

Authors:  Pascal Bucher; Gilles Chassot; Guillaume Zufferey; Frederic Ris; Olivier Huber; Philippe Morel
Journal:  World J Surg Oncol       Date:  2005-06-07       Impact factor: 2.754

5.  A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.

Authors:  Bo Ye; Shu-Geng Gao; Wang Li; Long-Hai Yang; Shou-Hua Zhao; Ke Ma; Xiao-Lei Zhu; Xiang-Yang Liu; Ke-Ling Sun
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

6.  Castleman's Disease-A Rare Diagnosis in the Retroperitoneum.

Authors:  Dakshyani S Nirhale; Ramchandra N Bharadwaj; Virendra S Athavale; Ruchita K Gupta; Charit Bora
Journal:  Indian J Surg       Date:  2011-05-12       Impact factor: 0.656

7.  Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.

Authors:  Xuanye Zhang; Huilan Rao; Xiaolu Xu; Zhihua Li; Bing Liao; Hongmei Wu; Mei Li; Xiuzhen Tong; Juan Li; Qingqing Cai
Journal:  Cancer Sci       Date:  2017-12-28       Impact factor: 6.716

8.  Castleman's disease: Laparoscopic resection of unicentric disease in the hepatic hilum: A case report.

Authors:  Frans Serpa Carmoma; Marta Cueva; Frans Serpa Carmoma; Gabriel A Molina; Alberto Yu Lee; Emilia Flores
Journal:  Ann Med Surg (Lond)       Date:  2021-06-09

9.  A Palpable Painless Axillary Mass as the Clinical Manifestation of Castleman's Disease in a Patient with Hepatitis C Disease.

Authors:  Athanasia K Papazafiropoulou; Angeliki M Angelidi; Antonis A Kousoulis; Georgios Christofilidis; Chariklia Sagia; Liountmila Kaftanidou; Kassiani Manoloudaki; Aikaterini Tsavari; Georgios Kranidiotis; Alexandros Kamaratos; Andreas Melidonis
Journal:  Case Rep Med       Date:  2016-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.